Ms. Iris Bincovich reports

INNOCAN PHARMA TO PROVIDE A CORPORATE UPDATE VIA ZOOM LIVESTREAM ON FEBRUARY 12, 2024, AT 4:00PM EST

Innocan Pharma Corp. will provide a corporate update to the investment community and its shareholders through a Zoom livestream on Feb. 12, 2024, at 4 p.m. EST.

The update will include a presentation by Innocan's chief executive officer, Iris Bincovich, describing the key research milestones achieved by the company to date.

Registration for the Zoom livestream is available.

About Innocan Pharma Corp.

Innocan is a pharmaceutical technology company that operates under two main segments: pharmaceuticals and consumer wellness. In the pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies composed of cannabinoid science to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) an LPT cannabidiol-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the bloodstream. The LPT delivery platform research is in the preclinical trial phase for pain management. In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative and high performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on developing advanced targeted on-line sales.